Survey analyses management of patients suffering from EGFRI toxicities

September 14, 2017

In an attempt to assess the similarities and differences in procedures, Liesbeth Lemmens from University Hospitals Leuven, Gasthuisberg in Belgium, surveyed seven nurses from hospitals in Belgium, Ireland, the Netherlands, Spain, Sweden, Switzerland and the United Kingdom. It was found that the management of EGFRI toxicities differed substantially between the nurses surveyed. This result may be expected since different types of EGFRIs, with different toxicity profiles, are used throughout Europe and there are a number of different treatment options available for these conditions. However, it is stated that standardised guidelines between European countries should improve patient care and may also be a useful resource for clinicians throughout Europe. In addition, standardised guidelines should focus on more information regarding patient education on lifestyle modifications, early symptoms of toxicity as well as regular patient assessment.

Lemmens concludes the article with the acknowledgement that the current work is an exploratory survey and is not necessarily representative of the entire European Union or of all hospitals within each country. However, the results from this survey can be used as a starting point for a more in-depth survey including a larger number of European countries.

Source: dx.doi/10.3332/ecancer.2011.220